Blake Weeks, DPM
Foot & Ankle Surgery · Beckley, WVNPI 1205191640
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,605 of the $4,117 with a category attached, or 87.6%. It is spread thinly across 39 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,301 and has fallen 63.0% since, to $481 in 2025.
Across 152 payments — averaging $27.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$764
- Organogenesis Inc.$475
- Smith+Nephew$474
- Paratek Pharmaceuticals, Inc.$200
- Musculoskeletal Transplant Foundation Inc.$181
- Kerecis Limited$177
- plus $2K from 33 others
What the payments were for
- Travel & lodging$48812%
- Food & beverage$3,60588%
- Entertainment$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 6 | $764 |
| Organogenesis Inc. | 30 | $475 |
| Smith+Nephew | 29 | $474 |
| Paratek Pharmaceuticals, Inc. | 11 | $200 |
| Musculoskeletal Transplant Foundation Inc. | 2 | $181 |
| Kerecis Limited | 3 | $177 |
| Piedmont Plus Innovation | 3 | $156 |
| Integra Lifesciences Corporation | 3 | $123 |
| Lifenet Health | 2 | $122 |
| Peerless Surgical Inc. | 1 | $110 |
| Abbott | 3 | $104 |
| Bioventus LLC | 5 | $93 |
| Progenacare Global, LLC | 1 | $90 |
| Next Science LLC | 6 | $87 |
| Tactile Systems Technology Inc | 5 | $85 |
| Amgen(2 entities) | 5 | $83 |
| Melinta Therapeutics, LLC | 4 | $77 |
| Avita Medical Americas, LLC | 1 | $76 |
| Treace Medical Concepts, Inc. | 3 | $72 |
| Inari Medical, Inc. | 3 | $70 |
| Novo Nordisk | 4 | $61 |
| ETS Wound Care LLC | 1 | $46 |
| GRT US Holding, Inc. | 2 | $42 |
| Cashflow Solutions, LLC | 2 | $42 |
| AbbVie | 2 | $38 |
| Nevro Corp. | 2 | $34 |
| Sanara Medtech Inc. | 1 | $27 |
| Mimedx Group, Inc. | 1 | $23 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $21 |
| TEI Medical Inc. | 1 | $20 |
| Kaleo, Inc. | 1 | $19 |
| Triad Life Sciences Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Orthofix Medical, Inc. | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Misonix Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,117 in reported general payments places this provider in the 65th percentile of 36 foot & ankle surgery providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 449 | $12,630 |
| SantylCollagenase Clostridium Hist. | 24 | $7,955 |
| Ammonium Lactate | 118 | $2,741 |
| Imiquimod | 62 | $2,354 |
| Diclofenac Sodium | 111 | $979 |
| Ketoconazole | 67 | $914 |
| Doxycycline Hyclate | 91 | $830 |
| Betamethasone Dipropionate | 32 | $796 |
| Meloxicam | 258 | $653 |
| Terbinafine Hcl | 68 | $598 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 41 | $492 |
| Cephalexin | 14 | $351 |
| Triamcinolone Acetonide | 12 | $282 |
| Clindamycin Hcl | 19 | $278 |
| Celecoxib | 24 | $195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $474 | $7,95524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 36 foot & ankle surgery providers in West Virginia.
Other foot & ankle surgery in Beckley
- Chinenye EzikeBeckley$11K
- Stefan LorinczBeckley$4K
- Ernest LuczkowskiBeckley$939
- Michael GentileHuntington$103K
- Carrie FrameCharleston$99K
- Kevin BrownHuntington$31K
- Jana AtikParkersburg$17K
- Kristin SilinskiParkersburg$16K
- Bradley HoffmanPrinceton$14K
- James PipesRipley$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.